Trial Profile
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine H7N9 (Primary) ; AS03A
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 10 Oct 2019 Status changed from active, no longer recruiting to completed.
- 30 May 2019 Planned End Date changed from 1 Aug 2019 to 30 Sep 2019.
- 30 May 2019 Planned primary completion date changed from 1 May 2019 to 30 Sep 2019.